In January 2019, she began the first-line therapy for HER2 + metastatic breast cancer with a combination of pertuzumab, trastuzumab, and paclitaxel, which was later replaced by endocrine therapy with anastrozole due to paclitaxel-induced peripheral neuropathy. The gene discussed is ERBB2; the disease is peripheral neuropathy.